Involvement of the central nervous system in acute lymphoblastic leukemia: opinions on molecular mechanisms and clinical implications based on recent data
L Lenk, A Alsadeq, DM Schewe - Cancer and Metastasis Reviews, 2020 - Springer
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. One of the major
clinical challenges is adequate diagnosis and treatment of central nervous system (CNS) …
clinical challenges is adequate diagnosis and treatment of central nervous system (CNS) …
Minimal residual disease monitoring with next-generation sequencing methodologies in hematological malignancies
Ultra-deep next-generation sequencing has emerged in recent years as an important
diagnostic tool for the detection and follow-up of tumor burden in most of the known …
diagnostic tool for the detection and follow-up of tumor burden in most of the known …
Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm
N Pemmaraju, NR Wilson, JD Khoury… - Blood, The Journal …, 2021 - ashpublications.org
COI notes: NP: Consulting/honorarium: AbbVie; Celgene; Stemline; Incyte; Novartis;
MustangBio; Roche Diagnostics, LFB, Sanofi, ImmunoGen; Research funding/clinical trials …
MustangBio; Roche Diagnostics, LFB, Sanofi, ImmunoGen; Research funding/clinical trials …
Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia …
S Paul, H Kantarjian, K Sasaki… - American journal …, 2023 - pubmed.ncbi.nlm.nih.gov
Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central
nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive …
nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive …
A higher dose of dasatinib may increase the possibility of crossing the blood–brain barrier in the treatment of patients with Philadelphia chromosome–positive acute …
X Gong, L Li, H Wei, B Liu, C Zhou, G Zhang, K Liu… - Clinical Therapeutics, 2021 - Elsevier
Purpose Dasatinib is a second-generation tyrosine kinase inhibitor with higher central
nervous system (CNS) penetration compared with imatinib and nilotinib in in vitro studies …
nervous system (CNS) penetration compared with imatinib and nilotinib in in vitro studies …
Management of CNS disease in pediatric acute lymphoblastic leukemia
JL McNeer, K Schmiegelow - Current hematologic malignancy reports, 2022 - Springer
Abstract Purpose of Review The treatment of acute lymphoblastic leukemia (ALL) is one of
the success stories of pediatric oncology, but challenges and questions remain, including …
the success stories of pediatric oncology, but challenges and questions remain, including …
Detection of kinase domain mutations in BCR:: ABL1 leukemia by ultra-deep sequencing of genomic DNA
R Sánchez, S Dorado, Y Ruíz-Heredia… - Scientific reports, 2022 - nature.com
The screening of the BCR:: ABL1 kinase domain (KD) mutation has become a routine
analysis in case of warning/failure for chronic myeloid leukemia (CML) and B-cell precursor …
analysis in case of warning/failure for chronic myeloid leukemia (CML) and B-cell precursor …
Prognostic significance of CNSL at diagnosis of childhood B-cell acute lymphoblastic leukemia: A report from the South China Children's Leukemia Group
LH Xu, X Geng, N Liao, LH Yang, HR Mai… - Frontiers in …, 2022 - frontiersin.org
Objectives The prognostic significance of acute lymphoblastic leukemia (ALL) patients with
central nervous system leukemia (CNSL) at diagnosis is controversial. We aimed to …
central nervous system leukemia (CNSL) at diagnosis is controversial. We aimed to …
Comparison of the efficacy and safety of ponatinib and dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia with central nervous system …
Y Zhu, Y Zhu, L Miao, T Jia, J Mao… - … in Cancer Research …, 2023 - journals.sagepub.com
Introduction Central nervous system leukemia (CNSL) is the most common extramedullary
relapse site in patients with Philadelphia chromosome-positive (Ph-positive) acute …
relapse site in patients with Philadelphia chromosome-positive (Ph-positive) acute …
Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL
G Gentile, T Poggio, A Catalano, M Voutilainen… - Blood …, 2024 - ashpublications.org
Abstract The t (1; 19) translocation, encoding the oncogenic fusion protein E2A (TCF3)-
PBX1, is involved in acute lymphoblastic leukemia (ALL) and associated with a pre–B-cell …
PBX1, is involved in acute lymphoblastic leukemia (ALL) and associated with a pre–B-cell …